Clinical Scorecard: Strategies for Reducing Infectious Risks in Hematopoietic Cell Transplant Patients: An International Overview
At a Glance
Category
Detail
Condition
Infectious complications in hematopoietic cell transplant (HCT) recipients
Key Mechanisms
Immune deficiency post-transplant, exposure to infectious agents, immune reconstitution variability, use of immunosuppressive therapy and graft-versus-host disease (GVHD)
Target Population
Pediatric and adult recipients of allogeneic and autologous hematopoietic cell transplants
Care Setting
HCT centers, transplant and infectious disease specialists, public health settings, and patient home environments
Key Highlights
Updated international guidelines reflect advances in antimicrobial agents, conditioning regimens, and donor sources since 2000.
Infections remain a leading cause of mortality post-HCT, accounting for 8% of deaths in autologous and 17–20% in allogeneic recipients.
Recommendations address prevention strategies across the transplant timeline, including donor selection, infection exposure prevention, and vaccination.
Guideline-Based Recommendations
Diagnosis
Define immune competence post-transplant as ability to receive live vaccines, generally at ~24 months without immunosuppression or active GVHD.
Consider patients with ongoing GVHD or immunosuppressive therapy as immune deficient and at high risk for infections.
Management
Apply evidence-based infection prevention strategies for allogeneic and autologous HCT recipients regardless of age.
Use new antimicrobial agents and supportive care measures tailored to patient risk and transplant type.
Consider similar infection prevention approaches for myeloablative and reduced-intensity conditioning due to limited comparative data.
Monitoring & Follow-up
Monitor immune recovery and infection risks longitudinally from donor selection through immune reconstitution.
Assess for infections caused by a broad range of pathogens, including emerging and region-specific organisms.
Risks
Recognize increased infection risk associated with immunosuppressive therapy and active GVHD.
Account for variability in local epidemiology, resource availability, and practice patterns when applying guidelines.
Patient & Prescribing Data
Hematopoietic cell transplant recipients including pediatric and adult, allogeneic and autologous types
Infection prevention requires individualized approaches considering conditioning regimen, donor source, immune status, and local infectious risks; adherence to guidelines may vary by region and resource availability.
Clinical Best Practices
Implement infection prevention measures throughout the transplant timeline, from donor selection to post-transplant immune recovery.
Educate patients, household contacts, and caregivers on infection prevention and vaccination schedules.
Incorporate multidisciplinary collaboration among transplant specialists, infectious disease experts, and public health professionals.
Adapt recommendations to local epidemiology and resource constraints while maintaining evidence-based standards.
Regularly update practices in response to emerging pathogens and advances in transplant care.
